Nephrotic Syndrome After Bevacizumab: Case Report and Literature Review
- 1 February 2007
- journal article
- case report
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 49 (2) , e23-e29
- https://doi.org/10.1053/j.ajkd.2006.11.024
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Proteinuria with and without Renal Glomerular Podocyte EffacementJournal of the American Society of Nephrology, 2006
- Bevacizumab—current status and future directionsAnnals of Oncology, 2005
- The Role of Vascular Endothelial Growth Factor in the Kidney in Health and DiseaseNephron Physiology, 2004
- Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetesActa Endocrinologica, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?Nephrology Dialysis Transplantation, 2003
- Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces ProteinuriaJournal of Biological Chemistry, 2003
- Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseasesJournal of Clinical Investigation, 2003
- Vascular endothelial growth factor is a survival factor for renal tubular epithelial cellsAmerican Journal of Physiology-Renal Physiology, 2000
- A case of membranous glomerulonephritis associated with adenocarcinoma of pancreas.Nephrology Dialysis Transplantation, 1998